282 Bispecific antibodies (BsAbs) targeting ABCB1/PgP and CD47 provide a multi-modal, tumor specific approach to combat drug resistant cancers

• Jessica Morgan,
• Cindy Tan,
• Suchismita Mohanty,
• Robert Arathoon,
• Raffaella Briante,
• Alissa O’Connor,
• Pamela Klein,
• Paul Ponath,
• Leonard Presta,
• Qianting Zhai,
• Pinping Zhang

Affiliations

Jessica Morgan

1 Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals Trust, Leeds, UK

Cindy Tan

Quality Improvement and Patient Experience, National University Hospital, Singapore, Singapore

Suchismita Mohanty

Arsenal Biosciences, South San Francisco, CA, USA

Robert Arathoon

1Kenjockety Biotechnology Inc., South San Francisco, CA, USA

Raffaella Briante

1Kenjockety Biotechnology Inc., South San Francisco, CA, USA

Alissa O’Connor

1Kenjockety Biotechnology Inc., South San Francisco, CA, USA

Pamela Klein

2PMK BioResearch, San Francisco, CA, USA

Paul Ponath

1Kenjockety Biotechnology Inc., South San Francisco, CA, USA

Leonard Presta

3Consultant, San Francisco, CA, USA

Qianting Zhai

4Abiosciences Inc., South San Francisco, CA, USA

Pinping Zhang

1Kenjockety Biotechnology Inc., South San Francisco, CA, USA